Physician profile
Karol Brown
NPI 1316297161
$949.51
in general payments reported to CMS, 2019-2025
12 companies · $251 in 2025
The $251 reported for 2025 was more than what 77% of Women'S Health (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $172 · 2022: $232 · 2023: $228 · 2024: $65.04 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $544.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $378.98 | 2021-2025 | |
| Hologic Sales and Service, LLC | $113.21 | 2025 | Thinprep 2000 Processor, Novasure |
| Sumitomo Pharma America, INC. | $82.96 | 2023-2025 | Myfembree, Gemtesa |
| Exeltis, USA INC. | $78.67 | 2022-2025 | Slynd |
| Avion Pharmaceuticals | $78.51 | 2021-2023 | Balcoltra |
| Biogen, INC. | $69.30 | 2025 | Zurzuvae |
| Pfizer INC. | $38.04 | 2023 | |
| Scynexis, INC. | $32.51 | 2022 | |
| Evofem Biosciences, INC. | $29.91 | 2021 | |
| Astellas Pharma US INC | $17.61 | 2023 | Veozah |
| Shield Therapeutics INC | $16.90 | 2023 | Accrufer |
| Myovant Sciences INC. | $12.91 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karol Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.